Protocol List

The Protocol List provides a listing of NCI clinical trials that are supported by the CTSU and are either active, near activation or temporarily closed. The list may be sorted by Protocol Number, Lead Organization, NIH Program, Status, or Phase. Clicking to the right of each title in the header row will display an arrow, an upwards facing arrow will sort by ascending order and a downwards facing arrow will display by descending order. Each protocol number is hyperlinked and clicking on the protocol number will open a new website, the National Cancer Institute’s Clinical Trials Physicians Data Query (PDQ®). PDQ provides additional information about each clinical trial including the trial summary, eligibility criteria and a listing of sites that have the trial open. The protocol list can be exported to and Excel or CSV file or printed by selecting the icon located above the header row.

*Some accruals have occurred outside of the CTSU systems and are collected manually, thus the total accrual number may not be accurate.
#Protocol NumberLead OrganizationNIH ProgramDiseaseStatusProtocol TitlePhaseAccrual TargetAccrual Total
  • First Page
  • Previous Page
  • Page 1 of 5
  • Next Page
  • Last Page
  • Last update: 12:24:44 AM UTC
1GOG-0238NRGNCTNFemale Reproductive System CancerActiveA Randomized Trial of Pelvic Irradiation with or Without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine CorpusII210136
2SCUSF-1102SCUSFNCORPBreast CancerActiveA Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics Services Among Breast Cancer PatientsOther37800
3DCP-001DCPNCORPHematopoietic Neoplasm (excluding Leukemia, Lymphoma and Myeloma);Miscellaneous and Metastatic CancerActiveUse of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)Other09051
4ARST1431COGNCTNSoft Tissue Cancer/SarcomaActiveA Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating with Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)III33747
59892LAO-PA015ETCTNAIDS-related Malignancy and Condition;Female Reproductive System CancerTemporarily Closed to AccrualPhase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination with Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vulvar CancerI640
69938LAO-PA015ETCTNMiscellaneous and Metastatic CancerActivePhase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid TumorsI5114
79924LAO-CA043ETCTNLymphomaActiveA Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL)I3011
89944LAO-MA036ETCTNFemale Reproductive System CancerActivePhase 2 Study of M6620 (VX-970) in Combination with gemcitabine versus gemcitabine alone in Subjects with Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube CancerII7044
9A021501ALLIANCENCTNGastrointestinal CancerTemporarily Closed to AccrualPreoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the PancreasII134112
109950LAO-MD017ETCTNHead and Neck CancerTemporarily Closed to AccrualA Phase I Study of M6620 (VX-970) in Combination with Cisplatin and XRT in Patients with Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121)I457
11NRG-GI002NRGNCTNGastrointestinal CancerTemporarily Closed to AccrualA Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal CancerII174178
12S1418SWOGNCTNBreast CancerActiveA Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant ChemotherapyIII1000193
13S1415CDSWOGNCORPBreast Cancer;Gastrointestinal Cancer;Lung, Mediastinal, and Pleural CancerActiveA Pragmatic Trial to Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)Other39601796
14A011502ALLIANCENCTNBreast CancerActiveA Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC TrialIII2936530
1510020LAO-CT018ETCTNBreast CancerTemporarily Closed to AccrualA Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)II908
169948LAO-MN026ETCTNFemale Reproductive System CancerActivePhase 1 Dose Escalation and Randomized Phase 2 Trial of Carboplatin and Gemcitabine with or without M6620 (VX-970) in First Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube CancerI/II245
179775LAO-MN026ETCTNLeukemiaActiveA Phase 2 Study of MLN0128 (TAK-228) in Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)II3512
18S1512SWOGNCTNSkin CancerActive A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)II7710
199910LAO-11030ETCTNLung, Mediastinal, and Pleural CancerActiveA Phase 1 Trial of MLN0128 (TAK-228) in Combination with Osimertinib (AZD9291) in Advanced EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) After Progression on a Previous EGFR Tyrosine Kinase InhibitorI3611
20EA8143ECOG-ACRINNCTNKidney CancerActiveA Phase 3 RandOmized Study Comparing PERioperative Nivolumab Vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)III76666
219979LAO-MN026ETCTNMiscellaneous and Metastatic CancerActivePhase 1 and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2-Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Brain MetastasesI472
229767LAO-CT018ETCTNUrothelial/ Bladder CancerActiveAn Open Label, Multicenter, Single Arm Phase II Study to Evaluate the Activity and Tolerability of the Novel mTOR Inhibitor, MLN0128 (TAK-228), in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract Whose Tumors Harbor a TSC1 and/or a TSC2 MutationII2095
239984LAO-CT018ETCTNMale Reproductive System CancerActiveA Randomized Phase 2 Study of Cediranib in Combination with Olaparib Versus Olaparib Alone in Men with Metastatic Castration Resistant Prostate CancerII9035
24A221502ALLIANCENCORPLung, Mediastinal, and Pleural CancerActivePulmonary Rehabilitation Before Lung Cancer ResectionIII1942
2510005LAO-NCIETCTNSoft Tissue Cancer/SarcomaActiveA Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part SarcomaII2618
2610031LAO-MA036ETCTNBreast Cancer;Female Reproductive System Cancer;Miscellaneous and Metastatic CancerActiveA Phase 1 Study of PARP Inhibitor Olaparib and HSP90 Inhibitor AT13387 for Treatment of Advanced Solid Tumors with Expansion in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, Peritoneal Cancer or Recurrent Triple-Negative Breast CancerI407
27S1616SWOGNCTNSkin CancerActiveA Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 AgentII9412
28EAF151ECOG-ACRINNCTNCNS Cancer (Primary tumor)ActiveChange in Relative Cerebral Blood Volume as a Biomarker for Early Response to Bevacizumab in Patients with Recurrent GlioblastomaII16513
2910013LAO-NC010ETCTNBreast CancerActiveRandomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, with or Without Atezolizumab in Triple Negative Breast Cancer (TNBC)II6030
30EA8134ECOG-ACRINNCTNMale Reproductive System CancerActiveInPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)III2006
31NRG-GI003NRGNCTNGastrointestinal CancerActiveA Phase III Randomized Trial of Protons Versus Photons for Hepatocellular CarcinomaIII1676
3210026LAO-MA036ETCTNLeukemiaActiveA Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid LeukemiaI486
33NRG-BR005NRGNCTNBreast CancerActiveA Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without SurgeryII17534
34EA1151ECOG-ACRINNCORPBreast CancerActiveTomosynthesis Mammographic Imaging Screening Trial (TMIST)III1649461670
359974EDDO-NY011MISCELLANEOUSLung, Mediastinal, and Pleural CancerActiveA Phase II Study of Olaparib Plus Cediranib in Combination with Standard Therapy for Small Cell Lung CancerII1325
3610009LAO-CT018ETCTNLeukemiaActiveA Phase 1b Study of the Anti-PD1 Antibody Pembrolizumab in Combination with the Histone Deacetylase Inhibitor, Entinostat for Treatment of Patients with Myelodysplastic Syndromes After DNA Methyltransferase Inhibitor Therapy FailureI275
3710042LAO-CT018ETCTNLung, Mediastinal, and Pleural CancerActiveA Phase II Trial of AZD9291 (Osimertinib) with or without Bevacizumab in Patients with EGFR Mutation Positive NSCLC and Brain MetastasesII980
3810030LAO-MD017ETCTNLeukemiaActiveA Phase 1 Study of Blinatumomab in Combination with Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients with Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaI306
3910015EDDO-MI014MISCELLANEOUSSoft Tissue Cancer/SarcomaActiveA Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients with Unresectable or Metastatic Epithelioid HemangioendotheliomaII2714
4010021LAO-MA036ETCTNGastrointestinal Cancer;Lung, Mediastinal, and Pleural CancerActiveA Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLCII18044
41NRG-GU003NRGNCTNMale Reproductive System CancerActiveA Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)III282216
42NRG-GY009NRGNCTNFemale Reproductive System CancerTemporarily Closed to AccrualA Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian CancerII/III48833
43A041501ALLIANCENCTNLeukemiaTemporarily Closed to AccrualA Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALLIII3246
44NRG-LU002NRGNCTNLung, Mediastinal, and Pleural CancerActiveMaintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III TrialII/III30010
45ADVL1622COGNCTNBone Cancer;Endocrine Cancer;Gastrointestinal Cancer;Kidney Cancer;Miscellaneous and Metastatic Cancer;Soft Tissue Cancer/SarcomaActivePhase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare TumorsII14659
46AALL15P1COGNCTNLeukemiaActiveA Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene RearrangementPilot11638
47A191402CDALLIANCENCORPMale Reproductive System CancerActiveTesting Decision Aids to Improve Prostate Cancer Decisions for Minority MenIII17265
48AGCT1531COGNCTNGerm Cell Cancer;Miscellaneous and Metastatic CancerActiveA Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell TumorsIII168083
49NRG-BN003NRGNCTNCNS Cancer (Primary tumor)ActivePhase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II MeningiomaIII13315
5010050LAO-NCIETCTNGastrointestinal CancerTemporarily Closed to AccrualA Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer Harboring KRAS G12R MutationsII2048